Shares of Lam Research slid 3.5% to $417.96 on July 1, giving back gains from a blistering rally, as investors digested a tug-of-war among Wall Street analysts: fresh price-target hikes tied to booming chip-equipment spending collided with a valuation-driven downgrade that warns the stock has run too far, too fast. LRCX is up over 110% year to date , and the question now is whether AI-fueled demand justifies a stock trading at a nosebleed premium.
The Bull Case Got Bigger Numbers — But So Did the Sticker Price
Cantor Fitzgerald on June 29 set a $500 price target, implying roughly 21% upside.
BofA lifted its target to $480 from $330, and Wells Fargo raised to $450 from $365 — all anchored to Lam's upgraded forecast that global spending on wafer fabrication equipment, the factory tools needed to make chips, will hit roughly $140 billion in 2026 , up from $135 billion. That's real money flowing into Lam's order book. But the stock now trades at a trailing price-to-earnings ratio exceeding 69 times, well above its historical five-year median , meaning investors are paying a steep premium for future growth that must actually arrive.
China Remains the Hidden Fault Line
China accounts for 34–35% of Lam's total revenue , and the company has already acknowledged a $200 million revenue hit from existing U.S. export restrictions . Management expects China's share to fall below 30% in 2026 as new rules limit shipments to certain domestic customers. Any further tightening could carve a much bigger hole in sales that no amount of AI enthusiasm can easily fill.
Record Earnings Are Real — But So Is the Speed of the Rally
Lam posted fiscal Q3 2026 revenue of $5.84 billion, up 24% year over year, with adjusted earnings per share up 41% — a genuine blowout. For the current quarter, guidance calls for $6.6 billion in revenue and record EPS of $1.65 . Yet company insiders have collectively sold $45 million more than they bought over the past 12 months , a pattern that suggests the people closest to the business see less upside than the stock price implies.
The Analyst Split Tells the Real Story
Among tracked analysts, roughly 79% rate LRCX a buy, 19% hold, and just 2% sell — but that lonely sell camp matters. The earlier Morgan Stanley downgrade to Underweight flagged exactly the risk now materializing: a trailing P/E past 69 times makes the stock severely vulnerable to sudden profit-taking . Today's 3.5% drop is a preview of what happens when momentum pauses and gravity reasserts itself.